Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu city, Oita 879-5593, Japan.
World J Gastroenterol. 2012 Jan 7;18(1):44-8. doi: 10.3748/wjg.v18.i1.44.
To investigate the effects of proton pump inhibitor (PPI) treatment on stool antigen test using the TestMate pylori enzyme immunoassay.
This study assessed 28 patients [16 men and 12 women; mean age (63.1 ± 5.9) years; range, 25-84 years] who underwent stool antigen test and urea breath test (UBT) before and after PPI administration.
Using the UBT as the standard, the sensitivity, specificity and agreement of the stool antigen test in all 28 patients were 95.2%, 71.4%, and 89.3%, respectively, before PPI administration, and 88.9%, 90.9%, and 89.3%, respectively, after PPI treatment. Mean UBT values were 23.98% ± 5.33% before and 16.19% ± 4.75% after PPI treatment and, in 15 patients treated for ≥ 4 wk, were significantly lower after than before 4 wk of PPI treatment (12.58% ± 4.49% vs 24.53% ± 8.53%, P = 0.048). The mean optical density (A(450/630)) ratios on the stool antigen test were 1.16 ± 0.20 before and 1.17 ± 0.24 after PPI treatment (P = 0.989), and were 1.02 ± 0.26 and 0.69 ± 0.28, respectively, in the group treated for > 4 wk (P = 0.099).
The stool antigen test was equally sensitive to the UBT, making it a useful and reliable diagnostic method, even during PPI administration.
研究质子泵抑制剂 (PPI) 治疗对 TestMate 幽门螺杆菌酶免疫测定法粪便抗原检测的影响。
本研究评估了 28 例患者[16 名男性和 12 名女性；平均年龄（63.1±5.9）岁；年龄范围 25-84 岁]，这些患者在接受 PPI 治疗前后均进行了粪便抗原检测和尿素呼气试验（UBT）。
使用 UBT 作为标准，在所有 28 例患者中，粪便抗原检测的灵敏度、特异性和一致性分别为 95.2%、71.4%和 89.3%，在接受 PPI 治疗前为 88.9%、90.9%和 89.3%，在接受 PPI 治疗后。UBT 值的平均值分别为治疗前的 23.98%±5.33%和治疗后的 16.19%±4.75%，在接受 PPI 治疗≥4 周的 15 例患者中，治疗 4 周后明显低于治疗前（12.58%±4.49% vs 24.53%±8.53%，P=0.048）。粪便抗原检测的平均光密度（A(450/630)）比值分别为治疗前的 1.16±0.20 和治疗后的 1.17±0.24（P=0.989），在治疗时间超过 4 周的组中分别为 1.02±0.26 和 0.69±0.28（P=0.099）。
粪便抗原检测对 UBT 具有同等的敏感性，使其成为一种有用且可靠的诊断方法，即使在 PPI 治疗期间也是如此。
